DDInter458 DDInter1355
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The DACH moiety also prevents cross-resistance with cisplatin and carboplatin. Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal cancer.[A796,A797] This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. Ongoing trials have also shown promising results for oxaliplatin use in nonHodgkin’s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer. Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin&reg;.
Cyclosporine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Cyclosporine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Cyclosporine {u} (Compound) upregulates {v} (Gene) GLRX
GLRX {u} (Gene) interacts with {v} (Gene) ATP7B
ATP7B {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Cyclosporine {u} (Compound) treats {v} (Disease) rheumatoid arthritis
rheumatoid arthritis {u} (Disease) upregulates {v} (Gene) ATP7B
ATP7B {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Cyclosporine {u} (Compound) binds {v} (Gene) ABCC2
ABCC2 {u} (Gene) is bound by {v} (Compound) Irinotecan
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Cyclosporine {u} (Compound) upregulates {v} (Gene) TMED10
TMED10 {u} (Gene) regulates {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Cyclosporine {u} (Compound) treats {v} (Disease) rheumatoid arthritis
rheumatoid arthritis {u} (Disease) is associated with {v} (Gene) MPO
MPO {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Cyclosporine {u} (Compound) upregulates {v} (Gene) GLRX
GLRX {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Cyclosporine {u} (Compound) downregulates {v} (Gene) IARS2
IARS2 {u} (Gene) is regulated by {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Cyclosporine {u} (Compound) upregulates {v} (Gene) TMED10
TMED10 {u} (Gene) is regulated by {v} (Gene) ABCC2
ABCC2 {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Cyclosporine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Oxaliplatin (Compound)
Cyclosporine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Cyclosporine (Compound) upregulates GLRX (Gene) and GLRX (Gene) interacts with ATP7B (Gene) and ATP7B (Gene) is bound by Oxaliplatin (Compound)
Cyclosporine (Compound) treats rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) upregulates ATP7B (Gene) and ATP7B (Gene) is bound by Oxaliplatin (Compound)
Cyclosporine (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Irinotecan (Compound) and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Cyclosporine (Compound) upregulates TMED10 (Gene) and TMED10 (Gene) regulates ABCG2 (Gene) and ABCG2 (Gene) is bound by Oxaliplatin (Compound)
Cyclosporine (Compound) treats rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is associated with MPO (Gene) and MPO (Gene) is bound by Oxaliplatin (Compound)
Cyclosporine (Compound) upregulates GLRX (Gene) and GLRX (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Cyclosporine (Compound) downregulates IARS2 (Gene) and IARS2 (Gene) is regulated by ABCG2 (Gene) and ABCG2 (Gene) is bound by Oxaliplatin (Compound)
Cyclosporine (Compound) upregulates TMED10 (Gene) and TMED10 (Gene) is regulated by ABCC2 (Gene) and ABCC2 (Gene) is bound by Oxaliplatin (Compound)